ReviewBiochemical Society transactions2011
An unexpected tail of VEGF and PlGF in pre-eclampsia.
Review in Biochemical Society transactions, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04855513 (Prevention of Pre-eclampsia Using Metformin), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Aberrant Uteroplacental and Vascular Signaling and Remodeling by Matrix Metalloproteinases in Pregnancy-Related Hypertension and Preeclampsia.Biomolecules · 2026Review
- IL-6 Polymorphism as a Predisposing Genetic Factor for Gestational Diabetes or Preeclampsia Development in Pregnancy with Obesity in Relation to VEGF and VEGFF Receptor Gene Expression Modalities.Diagnostics (Basel, Switzerland) · 2024Article
- Potential urinary biomarkers in preeclampsia: a narrative review.Molecular biology reports · 2024Review
- Reliability of Rodent and Rabbit Models in Preeclampsia Research.International journal of molecular sciences · 2022Review
- Blood biomarkers to predict the onset of pre-eclampsia: A systematic review and meta-analysis.Heliyon · 2022Article
- Maternal Obesity and Its Associated Factors and Outcomes in Klang Valley, Malaysia: Findings from National Obstetric Registry.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2021Article
- Angiogenesis, Lymphangiogenesis, and the Immune Response in South African Preeclamptic Women Receiving HAART.International journal of molecular sciences · 2019Review
- Evaluation of Placental VEGFA mRNA Expression in Preeclampsia: A Case Control Study.Journal of obstetrics and gynaecology of India · 2019Article
- Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice.The Journal of clinical investigation · 2018Article
- Molecular determinants of microvascular dysfunction in hypertensive pregnancy and preeclampsia.Microcirculation (New York, N.Y. : 1994) · 2018Article
- Negative Correlation between Placental Growth Factor and Endocan-1 in Women with Preeclampsia.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018Observational
- Overexpression of preeclampsia induced microRNA-26a-5p leads to proteinuria in zebrafish.Scientific reports · 2018Article
- The effects of sildenafil citrate on urinary podocin and nephrin mRNA expression in an L-NAME model of pre-eclampsia.Molecular and cellular biochemistry · 2017Article
- A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands.PLoS computational biology · 2017Article
- Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.Progress in molecular biology and translational science · 2017Review
- Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia.The Journal of endocrinology · 2017Review
- Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy.American journal of physiology. Regulatory, integrative and comparative physiology · 2016Article
- Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.Advances in pharmacology (San Diego, Calif.) · 2016Article
- Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.Biochemical pharmacology · 2015Review
- Concentrations of endothelial nitric oxide synthase, angiotensin-converting enzyme, vascular endothelial growth factor and placental growth factor in maternal blood and maternal metabolic status in pregnancy complicated by hypertensive disorders.Journal of human hypertension · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PET (pre-eclamptic toxaemia), characterized by pregnancy-related hypertension and proteinuria, due to widespread endothelial dysfunction, is a primary cause of maternal morbidity. Altered circulating factors, particularly the VEGF (vascular endothelial growth factor) family of proteins and their receptors, are thought to be key contributors to this disease. Plasma from patients with PET induces numerous cellular and physiological changes in endothelial cells, indicating the presence of a circulating imbalance of the normal plasma constituents. These have been narrowed down to macromolecules of the VEGF family of proteins and receptors. It has been shown that responses of endothelial cells in intact vessels to plasma from patients with pre-eclampsia is VEGF-dependent. It has recently been shown that this may be specific to the VEGF₁₆₅b isoform, and blocked by addition of recombinant human PlGF (placental growth factor). Taken together with results that show that sVEGFR1 (soluble VEGF receptor 1) levels are insufficient to bind VEGF-A in human plasma from patients with pre-eclampsia, and that other circulating macromolecules bind, but do not inactivate, VEGF-A, this suggests that novel hypotheses involving altered bioavailability of VEGF isoforms resulting from reduced or bound PlGF, or increased sVEGFR1 increasing biological activity of circulating plasma, could be tested. This suggests that knowing how to alter the balance of VEGF family members could prevent endothelial activation, and potentially some symptoms, of pre-eclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.